AUTHORS
Evangelos Terpos, MD, Maria Gavriatopoulou, MD2, Ioannis Ntanasis-Stathopoulos, MD3, Panagiotis Malandrakis, MD, MSc, PhD4, Nikolaos Kanellias, MD,PhD5, Yagnik Vyas6, Magdalini Migkou7, Foteini Theodorakakou, MD8, Eirini Solia, MD9, Evangelos Eleutherakis-Papaiakovou10, Efstathios Kastritis, MD11, Meletios-Athanasios (Thanos) C. Dimopoulos, MD12
AFFILIATIONS
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 Veeda Lifesciences, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 National and Kapodistrian University of Athens, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, Athens, Greece
12 Korea University, Seoul, Korea, Rep. of South, National and Kapodistrian University of Athens, Athens, Greece
ABSTRACT
Introduction The aim of this study was to evaluate safety, tolerability, and clinical activity of belantamab mafodotin (belamaf) plus lenalidomide and dexamethasone (Rd) (BelaRd) in transplant ineligible newly diagnosed multiple myeloma (TI-NDMM) patients (pts).
Methods BelaRd trial (NCT04808037) was a phase 1/2, open label study in frail and intermediate-fit pts with NDMM. In part 1 (n=36), we evaluated the safety/tolerability of belamaf 2.5/1.9/1.4 mg/kg every 8 weeks (Q8W) plus Rd and we established a recommended phase 2 dose (RP2D) of 1.9 mg/kg Q8W. In Part 2, n=30 pts were treated at RP2D and randomized 1:1 to Group (Gr) A (dose modification guided by ophthalmologist-assessed Keratopathy and Visual Acuity (KVA) scale or Gr B (hematologist-led Vision-Related Anamnestic (VRA) tool with ophthalmologist assessment focused on grade 3 ≥ ocular adverse events, OAEs). PFS was extrapolated using parametric survival models (Weibull, exponential, log-normal, log-logistic, and gamma). Projected median PFS (mPFS) and 95% confidence intervals (CIs) were estimated for the overall population and the RP2D subgroup.
Results At clinical cut off 15th May 2026, in Part 1, 21 pts (58.3%) remained on treatment, while 15 (41.7%) were discontinued. Reasons for discontinuation included AEs/SAEs (16.7%), and withdrawal of consent, death, and Disease progression (8.3% each). In Part 2, 19 patients (63.3%) remained on treatment and 11 (36.7%) discontinued. At baseline, ECOG PS was 1/2 in 52.8%/5.6% in part 1 and 56.7%/3.3% in part 2. R-ISS II/III in 75%/8.3% and 63.3%/10% of pts in part 1 and 2, respectively. High-risk cytogenetics was present in 8.3% of pts in part 1 and 16.7% pts in part 2. Median follow up was 53.7 months (range 3.2-62.0) in part 1 and 37.1 months (range 3.9-44.0) in part 2. Median treatment duration was 52.9 months (range 2.8-61.7) and 36.2 months (range 3.8-43.9) for part 1 and 2 respectively. Median belamaf exposure was 14.5 doses in part 1 and 12 doses in part 2. Median dose intensity was 0.5 mg/kg Q4W in both the parts with median relative dose intensity of 60.7% (range 17.6-95.7) and 40.4% (range 27.9-73.5), respectively. Overall response rate (ORR) (≥PR) was 100% in part 1 (sCR, 47.2%; CR, 13.9%; VGPR, 27.8%; and PR, 11.1%) and 93.3% in group A and 100% in group B of part 2. The median time to first response was 1.0 month (range 0.9-2.9) and time to best response was 19.2 and 12.6 months (range 1.0-47.2) and (range 1.1-30.7) for part 1 and 2, respectively. Overall MRD negativity at the time of CR in part 1 and 2 was achieved in 86.4% (19/22) and 94.1% (16/17) of MRD evaluable pts, respectively. The 12- and 24-months sustained MRD negativity rates were 66.6% (8/12) and 80% (12/15) of MRD evaluable pts, respectively. Overall median PFS & TTP were not reached. PFS rate at 24 months was 79.8% (95% CI 67.7-87.7) and for RP2D was 78.0% (95% CI 61.9-87.9). The TTP at 24 months was 98.2% (95% CI 88-99.8) and 97.2% (95% CI 81.9-99.6) for overall and RP2D population, respectively. Projected mPFS for the overall pts ranged from 84.6-105.3 months (7-8.7 years) and for RP2D ranged from 83.9 to 99.5 months (6.9-8.3 years). OS rate at 24 months was 81.6% (95% CI 69.8-89.1) and for RP2D was 80.7% (95% CI 65.1-89.9). Dose holds occurred in 34.3% in part 1 (OAEs) and in 22.7% in Gr A (OAEs) versus 2.7% in Gr B (VRA-guided).
Conclusions Belamaf plus Rd demonstrated rapid, deep, and durable responses in transplant-ineligible intermediate-fit/frail NDMM, with high ORR, sustained disease control, and high PFS and MRD negativity rates. Model-based analyses predicted mPFS exceeding that observed with DRd and similar to that observed with quadruplets regimens.
Funding by GSK (NCT04808037); authors solely responsible for content.
DISCLOSURES
Evangelos Terpos, MD: Johnson & Johnson - Honoraria; GSK - Honoraria; Forus - Honoraria; Pfizer - Honoraria; Amgen - Honoraria; Menarini/Stemline - Honoraria; Sanofi - Honoraria; Takeda - Honoraria; Swixx - Honoraria; EUSA Pharma - Honoraria; BMS - Honoraria; Antengene - Honoraria; Sanofi - Research Funding; GSK - Research Funding; Johnson & Johnson - Research Funding; Menarini/Stemline - Research Funding; GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony)